Sills R H
Am J Pediatr Hematol Oncol. 1984 Winter;6(4):431-9.
Thrombotic thrombocytopenic purpura is a life-threatening disorder which requires immediate therapy. Unfortunately, there are no widely accepted therapeutic recommendations for this rare disorder. The literature contains large numbers of uncontrolled and often uncomparable studies of a variety of therapies used in differing combinations. This article attempts to rationalize the therapy of thrombotic thrombocytopenic purpura based on our current understanding of its pathophysiology. The rationale of each therapeutic modality, including plasma therapy, corticosteroids, vincristine, antiplatelet agents, and splenectomy, is discussed. This is followed by an overview of the clinical results reported in the literature for these individual treatments. Finally, overall therapeutic guidelines for the therapy of thrombotic thrombocytopenic purpura are presented. It is hoped that these guidelines will clarify the treatment of this disorder until more definitive therapeutic studies are available.
血栓性血小板减少性紫癜是一种危及生命的疾病,需要立即治疗。不幸的是,对于这种罕见疾病,目前尚无广泛接受的治疗建议。文献中包含大量关于各种疗法的无对照且往往不可比的研究,这些疗法以不同组合使用。本文试图根据我们目前对其病理生理学的理解,对血栓性血小板减少性紫癜的治疗进行合理化分析。讨论了包括血浆疗法、皮质类固醇、长春新碱、抗血小板药物和脾切除术在内的每种治疗方式的原理。接下来是文献中报道的这些个体治疗的临床结果概述。最后,给出了血栓性血小板减少性紫癜治疗的总体指导原则。希望这些指导原则能在有更确切的治疗研究之前,明确该疾病的治疗方法。